logo

Adc Therapeutics (ADCT)



Trade ADCT now with
  Date
  Headline
5/6/2021 7:08:56 AM ADC Therapeutics Q1 Loss Per Share $0.67 Vs Loss Per Share $0.85 Year Ago
4/6/2021 7:07:33 AM Overland ADCT BioPharma Appoints Eric Koo CEO
4/6/2021 7:03:09 AM Overland ADCT BioPharma Appoints Eric Koo As CEO
3/18/2021 7:04:39 AM ADC Therapeutics Q4 Loss/Shr $0.73 Vs Loss $0.69 Last Year
2/4/2021 7:35:01 AM ADC Therapeutics Completes Enrollment In Pivotal Phase 2 Clinical Trial Of Cami In R/r Hodgkin Lymphoma
1/7/2021 7:21:25 AM ADC Therapeutics Initiates Expanded Access Program For Loncastuximab Tesirine In The U.S. In DLBCL
12/15/2020 9:08:42 AM ADC And Overland Pharma Form JV To Expand ADC Drugs Development And Commercialization In China And Singapore
12/7/2020 7:09:20 AM ADC Therapeutics: Encouraging Data Presented At 2020 ASH Meeting Reinforce Significant Progress Made With PBD-based ADCs
11/20/2020 7:04:49 AM ADC:FDA Grants Priority Review For Lonca For Treatment Of Relapsed/Refractory Diffuse Large B-cell Lymphoma
11/12/2020 7:04:54 AM ADC Therapeutics Q3 Loss Per Share $0.29; Adj Loss Per Share $0.58
11/3/2020 7:19:39 AM ADC Therapeutics Announces First Patient Dosed With Camidanlumab Tesirine With Pembrolizumab In Phase 1b Trial
10/30/2020 7:23:01 AM Genmab And ADC Therapeutics Announce Amended Agreement For Camidanlumab Tesirine
9/23/2020 9:34:15 PM ADC Therapeutics Announces Pricing Of Upsized Public Offering Of 6 Mln Shares At $34.00/shr